Literature DB >> 18470943

The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.

Yoko Aoki1, Tetsuya Niihori, Yoko Narumi, Shigeo Kure, Yoichi Matsubara.   

Abstract

The RAS proteins and their downstream pathways play pivotal roles in cell proliferation, differentiation, survival and cell death, but their physiological roles in human development had remained unknown. Noonan syndrome, Costello syndrome, and cardio-facio-cutaneous (CFC) syndrome are autosomal dominant multiple congenital anomaly syndromes characterized by a distinctive facial appearance, heart defects, musculocutaneous abnormalities, and mental retardation. A variety of mutations in protein tyrosine phosphatase, non-receptor type 11(PTPN11) has been identified in 50% of Noonan patients. Specific mutations in PTPN11 have been identified in LEOPARD (multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and sensorineural deafness) syndrome. In 2005, we discovered Harvey-RAS (HRAS) germline mutations in patients with Costello syndrome. This discovery provided a clue to identification of germline mutations in Kirsten-RAS (KRAS), BRAF and mitogen-activated protein kinase kinase 1 and 2 (MAP2K1/MAP2K2) in patients with CFC syndrome. These genes encode molecules in the RAS/RAF/MEK/extracellular signal-regulated kinase (ERK) pathway, leading to a new concept that clinically related disorders, i.e., Noonan, Costello, and CFC syndromes are caused by dysregulation of the RAS/mitogen activated protein kinase (MAPK) pathway. In the present review, we summarize mutations in HRAS, KRAS, BRAF, MAP2K1/2, and PTPN11, the phenotypes of patients with these mutations, the functional properties of mutants and animal models. Finally we suggest that disorders with mutations of molecules in the RAS/MAPK cascade (Noonan, LEOPARD, Costello, and CFC syndromes and neurofibromatosis type I) may be comprehensively termed "the RAS/MAPK syndromes." Details on mutations will be updated in the RAS/MAPK Syndromes Homepage (www.medgen.med.tohoku.ac.jp/RasMapk syndromes.html).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470943     DOI: 10.1002/humu.20748

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  124 in total

1.  Regulation of kidney development by Shp2: an unbiased stereological analysis.

Authors:  Frank S David; Luise Cullen-McEwen; Xue Sue Wu; Stephen R Zins; Julie Lin; John F Bertram; Benjamin G Neel
Journal:  Anat Rec (Hoboken)       Date:  2010-08-23       Impact factor: 2.064

2.  Outcome of array CGH analysis for 255 subjects with intellectual disability and search for candidate genes using bioinformatics.

Authors:  Y Qiao; C Harvard; C Tyson; X Liu; C Fawcett; P Pavlidis; J J A Holden; M E S Lewis; E Rajcan-Separovic
Journal:  Hum Genet       Date:  2010-05-29       Impact factor: 4.132

Review 3.  Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale.

Authors:  Beth A Rose; Thomas Force; Yibin Wang
Journal:  Physiol Rev       Date:  2010-10       Impact factor: 37.312

4.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 5.  Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.

Authors:  Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink
Journal:  Nitric Oxide       Date:  2014-08-19       Impact factor: 4.427

6.  Germline-Activating RRAS2 Mutations Cause Noonan Syndrome.

Authors:  Tetsuya Niihori; Koki Nagai; Atsushi Fujita; Hirofumi Ohashi; Nobuhiko Okamoto; Satoshi Okada; Atsuko Harada; Hirotaka Kihara; Thomas Arbogast; Ryo Funayama; Matsuyuki Shirota; Keiko Nakayama; Taiki Abe; Shin-Ichi Inoue; I-Chun Tsai; Naomichi Matsumoto; Erica E Davis; Nicholas Katsanis; Yoko Aoki
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

7.  Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.

Authors:  Yuka Saito; Yoko Aoki; Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski; Masue Imaizumi; Takeshi Rikiishi; Yoji Sasahara; Shigeo Kure; Tetsuya Niihori; Shigeru Tsuchiya; Seiji Kojima; Yoichi Matsubara
Journal:  Leuk Res       Date:  2012-05-14       Impact factor: 3.156

Review 8.  Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

Authors:  Thomas Force; Kyle L Kolaja
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 9.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

Review 10.  Molecular origins of cancer: Molecular basis of colorectal cancer.

Authors:  Sanford D Markowitz; Monica M Bertagnolli
Journal:  N Engl J Med       Date:  2009-12-17       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.